Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection

Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other diseases related to dysregulated aldosterone [1][5] - The company announced that data from the pivotal Phase 3 Launch-HTN trial for lorundrostat, targeting uncontrolled hypertension (uHTN) and resistant hypertension (rHTN), will be presented at the 34th European Meeting on Hypertension and Cardiovascular Protection [1][2] Group 1: Lorundrostat Overview - Lorundrostat is an orally administered, highly selective aldosterone synthase inhibitor designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production [3] - It has a 374-fold selectivity for aldosterone-synthase inhibition compared to cortisol-synthase inhibition in vitro, with a half-life of 10-12 hours and a demonstrated 70% reduction in plasma aldosterone concentration in hypertensive subjects [3] Group 2: Clinical Trial Details - The Phase 2 proof-of-concept trial (Target-HTN) showed that once-daily lorundrostat resulted in clinically meaningful blood pressure reduction in both automated office blood pressure measurement and 24-hour ambulatory blood pressure monitoring [4] - Adverse events included a modest increase in serum potassium, decrease in estimated glomerular filtration rate, urinary tract infection, and one serious adverse event of hyponatremia possibly related to the study drug [4] Group 3: Company Background - Mineralys Therapeutics is based in Radnor, Pennsylvania, and was founded by Catalys Pacific, focusing on cardiorenal conditions affected by dysregulated aldosterone [5]